If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
4.085    0.035 (0.86%)
Bid:
3.70
Ask:
3.90
Spread: 0.20 (5.405%)
Market Cap: £25.49m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Total Voting Rights

16 Aug 2022 08:03

RNS Number : 0957W
Immupharma PLC
16 August 2022
 

RNS | 16 August 2022 

ImmuPharma plc

Total Voting Rights

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote. As the Company does not hold any shares in treasury, the total number of voting rights in the Company is also 327,403,115 and this figure of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information, please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer & Chairman

+ 44 (0) 207 152 4080

Lisa Baderoon, Head of Investor Relations & Non-Executive Director

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 20 3650 3650

 

 

+44 (0) 1483 413500

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRSFIESIEESEEA
Date   Source Headline
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM
4th May 20167:00 amRNSFinal Results
26th Apr 20167:00 amRNSNotice of Results
22nd Apr 20169:50 amRNSHolding(s) in Company
9th Mar 20167:00 amRNSFirst European Site Opens - Patient Recruitment
8th Mar 201611:10 amRNSHolding(s) in Company
7th Mar 20163:31 pmRNSHolding(s) in Company
1st Mar 20167:00 amRNSEIS and VCT Qualifying Status and Issue of Equity
29th Feb 20168:02 amRNSHolding(s) in Company
24th Feb 201612:35 pmRNSIssue of Equity
22nd Feb 20161:39 pmRNSResult of GM
15th Feb 20167:00 amRNSUS PATIENTS COMMENCE DOSING IN PHASE III STUDY
5th Feb 201612:22 pmRNSPlacing and Subscription Raises £8.3 million
5th Feb 20167:00 amRNSProposed Placing and Subscription
21st Jan 20165:33 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSImmuPharma & Simbec-Orion - Investigators Meeting
7th Dec 20157:00 amRNSUpdate on the progress of Lupuzor
30th Nov 201511:55 amRNSHolding(s) in Company
4th Nov 20158:26 amRNSLupuzor Phase III Pivotal Trial Update
4th Nov 20157:00 amRNSLupuzor Phase III Pivotal Trial Update
23rd Oct 20157:00 amRNSDirectorate Change
30th Sep 20157:05 amRNSDirectorate Change
30th Sep 20157:00 amRNSInterim Results
29th Jul 20157:00 amRNSRichard Warr
27th Jul 20157:00 amRNSTERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25th Jun 20157:00 amRNSLupuzor's Founder Dr Slyviane Muller Awarded Medal
29th May 201512:50 pmRNSResult of AGM
6th May 20153:44 pmRNSAnnual Report & Accounts
6th May 20157:02 amRNSInterim Board Change
30th Apr 20157:05 amRNSDirectorate Change
30th Apr 20157:00 amRNSPreliminary Results
11th Feb 201512:02 pmRNSCANCER UPDATE: IPP-204106
27th Jan 20157:00 amRNSEnterprise Investment Scheme Status
22nd Jan 20157:00 amRNSCollaboration Agreement with Simbec-Orion
30th Oct 201411:10 amRNSHolding(s) in Company
28th Oct 20147:00 amRNSHolding(s) in Company
21st Oct 20147:00 amRNSAdditional Listing - Conditional Placing
20th Oct 20147:00 amRNSImmuPharma awarded EUR400,000 Grant
30th Sep 20147:05 amRNSHalf Yearly Report
30th Sep 20147:00 amRNSLupuzorT Gears Up To Start Pivotal Phase III trial
27th Jun 20141:11 pmRNSResult of AGM
27th Jun 20147:00 amRNSAccess to pioneering research in Bordeaux France
16th Jun 20147:00 amRNSNEW NUCANT PATENTS
23rd May 20147:00 amRNSAnnual Financial Report
21st May 20147:00 amRNSPreliminary Results
6th May 201412:47 pmRNSDr. Sylviane Muller - Presentation Abstract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.